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Solid-organ transplant recipients requiring chronic immunosuppressive therapy 
experience a substantially increased incidence of aggressive malignancies, of which 
cutaneous malignancies are most common (DiGiovanna, 1998; Berg and Otley, 2002). 
In some studies, skin cancers have been estimated to occur at a greater than 65-fold 
increased frequency in transplant recipients than in the general population (Hartevelt 
et al., 1990; Jensen et al., 1999). This increased risk of skin cancer is likely due to a 
combination of previous and ongoing UV light exposure and pharmacologic immune 
suppression. (Hojo et al., 1997)
Additionally, tumors in immunosuppressed transplant patients seem to be more aggressive than tumors found in 
the general population. The risk of metastasis from cutaneous squamous cell carcinoma in organ transplant patients 
is approximately 7%, significantly greater than that of the general population. Furthermore, in transplant recipients 
from Sydney, Australia, 27% of deaths (4 years after transplantation) were due to metastatic skin cancer (Ong et al., 
1999; Otley and Maragh, 2005). Clearly, reducing the risk of aggressive skin cancers in immunosuppressed transplant 
recipients is a significant clinical challenge.
Wulff and colleagues (2008, this issue) studied two immunosuppressive medications commonly used after 
transplantation—cyclosporine A (CsA) and sirolimus (SRL)—to determine their individual and combined effects 
on tumor development. In murine models exposed to UV light, the authors reported enhanced tumor size and 
progression in CsA-treated mice. These clinical observations were associated with increased dermal mast cell numbers 
and higher levels of transforming growth factor (TGF)-β1 in the skin. However, UV light–exposed mice that received 
either SRL or CsA plus SRL exhibited fewer tumors, with diminished size and reduced progression compared with 
vehicle-treated mice. Dermal mast cells and TGF-β1 levels were not increased in these mice. These findings suggest 
the potential utility of SRL (whether or not CsA is used) in protecting transplant patients (and perhaps others) from 
developing skin cancer.
Through the following questions, we examine this paper in greater detail. For brief answers, please refer to http://
network.nature.com/group/jidclub.
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QUESTIONS
1. What is the clinical evidence that immunosuppression increases skin cancer risk?
2. Why is sirolimus potentially a chemopreventive agent?
3. How well did the experimental model replicate the clinical scenario depicted by the researchers?
4. What were the major findings of the study?
5. What are the proposed mechanisms by which sirolimus might work?
6. What may be the clinical implications of this article?
7. What further studies could be performed?
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